1. Genetic and chemical inhibition of IRF5 suppresses pre-existing mouse lupus-like disease
- Author
-
Ryusuke Yoshimi, Tadatsugu Taniguchi, Hideyuki Yanai, Shuichi Suzuki, Akira Nishiyama, Hideaki Nakajima, Tadashi Yamamoto, Shuichi Ito, Kappei Tsukahara, Yohei Kirino, Noriko Tagata, Go R. Sato, Kenichi Nishimura, Tatsuma Ban, Hiroe Hihara, Masako Kikuchi, Akio Manabe, Masashi Ito, Kentaro Yoshimatsu, Yoshiko Matsumoto, Kayo Harita, and Tomohiko Tamura
- Subjects
0301 basic medicine ,Male ,PATHOGENESIS ,INTERFERON REGULATORY FACTOR ,General Physics and Astronomy ,PROTECTS MICE ,Autoimmunity ,Disease ,Receptor, Interferon alpha-beta ,medicine.disease_cause ,Kidney ,Mice ,0302 clinical medicine ,Interferon ,immune system diseases ,Lupus Erythematosus, Systemic ,skin and connective tissue diseases ,Innate immunity ,Mice, Knockout ,Multidisciplinary ,Systemic lupus erythematosus ,DEFICIENCY ,src-Family Kinases ,PLASMA-CELLS ,B-CELLS ,Interferon Regulatory Factors ,Female ,Signal transduction ,medicine.drug ,Signal Transduction ,ERYTHEMATOSUS ,Science ,DENDRITIC CELLS ,General Biochemistry, Genetics and Molecular Biology ,Article ,Target validation ,Autoimmune Diseases ,03 medical and health sciences ,medicine ,Animals ,Humans ,Autoantibodies ,030203 arthritis & rheumatology ,Autoimmune disease ,Lupus erythematosus ,business.industry ,General Chemistry ,medicine.disease ,Immunity, Innate ,Mice, Inbred C57BL ,030104 developmental biology ,Gene Expression Regulation ,Immunoglobulin G ,Cancer research ,ALPHA ACTIVITY ,business ,IRF5 ,Transcription Factors - Abstract
The transcription factor IRF5 has been implicated as a therapeutic target for the autoimmune disease systemic lupus erythematosus (SLE). However, IRF5 activation status during the disease course and the effects of IRF5 inhibition after disease onset are unclear. Here, we show that SLE patients in both the active and remission phase have aberrant activation of IRF5 and interferon-stimulated genes. Partial inhibition of IRF5 is superior to full inhibition of type I interferon signaling in suppressing disease in a mouse model of SLE, possibly due to the function of IRF5 in oxidative phosphorylation. We further demonstrate that inhibition of IRF5 via conditional Irf5 deletion and a newly developed small-molecule inhibitor of IRF5 after disease onset suppresses disease progression and is effective for maintenance of remission in mice. These results suggest that IRF5 inhibition might overcome the limitations of current SLE therapies, thus promoting drug discovery research on IRF5 inhibitors., IRF5 is a potential target for therapy in systemic lupus erythematosus (SLE). Here the authors show using mouse SLE-like models that genetic or chemical inhibition of IRF5 after SLE onset could be more effective than, or an add on for, currently utilised type I interferon inhibition.
- Published
- 2021